Malaria with other antimalarials (known as artemisinin-combination therapy, or ACT), which decreases resistance to any single drug component. These additional antimalarials include: amodiaquine, lumefantrine, mefloquine or sulfadoxine/pyrimethamine. Another recommended combination is dihydroartemisinin and piperaquine. ACT is about 90% effective when used to treat uncomplicated malaria. To treat malaria during pregnancy, the WHO recommends the use of quinine plus clindamycin early in the pregnancy (1st trimester), and ACT in later stages (2nd and 3rd trimesters). In the 2000s (decade), malaria with partial resistance to artemisins emerged in Southeast Asia. Infection with "P. vivax", "P. ovale" or "P. malariae" usually do not require
Effects of global warming of dengue fever deaths worldwide in 2004. Total attributable mortality was about 0.2% of deaths in 2004; of these, 85% were child deaths. With high confidence, authors of the IPCC AR4 Synthesis report projected that climate change would bring some benefits in temperate areas, such as fewer deaths from cold exposure, and some mixed effects such as changes in range and transmission potential of malaria in Africa. Benefits were projected to be outweighed by negative health effects of rising temperatures, especially in developing countries. With very high confidence, Confalonieri "et al." (2007) concluded that economic development was an important component